236 related articles for article (PubMed ID: 30616596)
1. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries.
Saida T; Yamamura T; Kondo T; Yun J; Yang M; Li J; Mahadavan L; Zhu B; Sheikh SI
BMC Neurol; 2019 Jan; 19(1):5. PubMed ID: 30616596
[TBL] [Abstract][Full Text] [Related]
2. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
4. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC
Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854
[TBL] [Abstract][Full Text] [Related]
6. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension.
Kondo T; Kawachi I; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Mult Scler J Exp Transl Clin; 2019; 5(3):2055217319864974. PubMed ID: 31391949
[TBL] [Abstract][Full Text] [Related]
8. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Miller DH; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Kita M; Wheeler-Kingshott CA; Tozer DJ; MacManus DG; Yousry TA; Goodsell M; Yang M; Zhang R; Viglietta V; Dawson KT;
Neurology; 2015 Mar; 84(11):1145-52. PubMed ID: 25681448
[TBL] [Abstract][Full Text] [Related]
9. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
O'Gorman J; Russell HK; Li J; Phillips G; Kurukulasuriya NC; Viglietta V
Clin Ther; 2015 Jul; 37(7):1402-1419.e5. PubMed ID: 25999183
[TBL] [Abstract][Full Text] [Related]
10. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
11. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Kappos L; Giovannoni G; Gold R; Phillips JT; Arnold DL; Hotermans C; Zhang A; Viglietta V; Fox RJ;
Eur J Neurol; 2015 Apr; 22(4):664-71. PubMed ID: 25557371
[TBL] [Abstract][Full Text] [Related]
12. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
Koulinska I; Riester K; Chalkias S; Edwards MR
Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
[TBL] [Abstract][Full Text] [Related]
13. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L; Gold R; Miller DH; Macmanus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Yang M; Eraksoy M; Meluzinova E; Rektor I; Dawson KT; Sandrock AW; O'Neill GN;
Lancet; 2008 Oct; 372(9648):1463-72. PubMed ID: 18970976
[TBL] [Abstract][Full Text] [Related]
15. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT
J Neurol; 2014 Sep; 261(9):1794-802. PubMed ID: 24989666
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
[TBL] [Abstract][Full Text] [Related]
17. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Blair HA
Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
19. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT
J Neurol; 2014 Dec; 261(12):2429-37. PubMed ID: 25270680
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
